{"id":510134,"date":"2021-07-07T07:18:08","date_gmt":"2021-07-07T11:18:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/"},"modified":"2021-07-07T07:18:08","modified_gmt":"2021-07-07T11:18:08","slug":"cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/","title":{"rendered":"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference"},"content":{"rendered":"
\n

BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference held July 13-14, 2021. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel\u2019s business followed by an analyst-led fireside chat.<\/p>\n

\n Presentation Information:<\/strong>\n <\/p>\n\n\n\n\n
\n Date:<\/strong>\n <\/td>\n\u00a0<\/td>\nWednesday, July 14<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n\u00a0<\/td>\n10:30-10:55 am EDT<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\n\u00a0<\/td>\nVirtual; Track 1<\/td>\n<\/tr>\n<\/table>\n

\n Investor registration: <\/strong>
\n
\n click here<\/strong>
\n <\/a>
\n \n <\/p>\n

The webcast will be archived for 90 days and can be found on the Cyclacel website at www.cyclacel.com<\/a>.<\/p>\n

\n About\u00a0Cyclacel Pharmaceuticals, Inc. <\/strong>\n <\/p>\n

Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies.\u00a0Cyclacel’s\u00a0strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit\u00a0www.cyclacel.com<\/a>.<\/p>\n

\n Forward-looking Statements <\/strong>\n <\/p>\n

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel\u2019s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and\/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling,\u00a0Cyclacel\u00a0may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the potential effects of the COVID-19 pandemic, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the\u00a0Securities and Exchange Commission\u00a0and are available at\u00a0www.sec.gov<\/a>. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n
Company:<\/td>\nPaul McBarron, (908) 517-7330,\u00a0pmcbarron@cyclacel.com<\/u><\/a><\/td>\n<\/tr>\n
Investor Relations:<\/td>\nLifeSci Advisors, LLC,\u00a0Irina Koffler, (646) 970-4681,\u00a0ikoffler@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\u00a9 Copyright 2021 Cyclacel. All Rights Reserved. The\u00a0Cyclacel\u00a0logo and\u00a0Cyclacel\u00ae<\/sup>\u00a0are trademarks of\u00a0Cyclacel.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference held July 13-14, 2021. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel\u2019s business followed by an analyst-led fireside chat. Presentation Information: Date: \u00a0 Wednesday, July 14 Time: \u00a0 10:30-10:55 am EDT Location: \u00a0 Virtual; Track 1 Investor registration: click here The webcast will be archived for 90 days and can be found on the Cyclacel website at www.cyclacel.com. About\u00a0Cyclacel Pharmaceuticals, Inc. Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines … <\/p>\n

Continue reading “Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510134","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference held July 13-14, 2021. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel\u2019s business followed by an analyst-led fireside chat. Presentation Information: Date: \u00a0 Wednesday, July 14 Time: \u00a0 10:30-10:55 am EDT Location: \u00a0 Virtual; Track 1 Investor registration: click here The webcast will be archived for 90 days and can be found on the Cyclacel website at www.cyclacel.com. About\u00a0Cyclacel Pharmaceuticals, Inc. Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines … Continue reading "Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T11:18:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference\",\"datePublished\":\"2021-07-07T11:18:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/\"},\"wordCount\":519,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/\",\"name\":\"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=\",\"datePublished\":\"2021-07-07T11:18:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference held July 13-14, 2021. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel\u2019s business followed by an analyst-led fireside chat. Presentation Information: Date: \u00a0 Wednesday, July 14 Time: \u00a0 10:30-10:55 am EDT Location: \u00a0 Virtual; Track 1 Investor registration: click here The webcast will be archived for 90 days and can be found on the Cyclacel website at www.cyclacel.com. About\u00a0Cyclacel Pharmaceuticals, Inc. Cyclacel\u00a0is a clinical-stage, biopharmaceutical company developing innovative cancer medicines … Continue reading \"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T11:18:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference","datePublished":"2021-07-07T11:18:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/"},"wordCount":519,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/","name":"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=","datePublished":"2021-07-07T11:18:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjU5MyM0Mjg2NDQ1IzIwMDY3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann\u2019s Virtual 2021 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510134"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510134\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}